Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Inogen Inc Market Cap
The Inogen Inc (INGN) share price is expected to increase by 2.99% over the next year. This is based on calculating the average 12-month share price estimate provided by 4 stock analysts who have covered INGN. Price targets range from $10 at the low end to $10 at the high end. The current analyst consensus for INGN is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned INGN 1 buy ratings, 2 hold ratings, and 1 sell ratings. This means that analysts expect Inogen Inc to generate similar returns as the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on INGN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of INGN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Mike Matson Needham | Hold | Reiterates | Nov 8, 2024 | |
| Mike Matson Needham | Hold | Reiterates | Aug 7, 2024 | |
| Mike Matson Needham | Hold | Reiterates | May 8, 2024 | |
| Mathew Blackman Stifel | Hold | $7 | Maintains | May 8, 2024 |
| Mike Matson Needham | Hold | Reiterates | Apr 9, 2024 | |
| Margaret Kaczor William Blair | Outperform | Upgrade | Feb 15, 2024 | |
| Robbie Marcus JP Morgan | Underweight | $7 | Maintains | Nov 8, 2023 |
| Robbie Marcus JP Morgan | Underweight | $8 | Downgrade | Aug 8, 2023 |
| Mathew Blackman Stifel | Hold | $8 | Maintains | Aug 8, 2023 |
| Mike Matson Needham | Hold | Downgrade | Jul 14, 2023 | |
| Mike Matson Needham | Buy | $26 | Reiterates | Apr 20, 2023 |
| Mike Matson Needham | Buy | $26 | Reiterates | Feb 28, 2023 |
| Mike Matson Needham | Buy | $26 | Maintains | Feb 24, 2023 |
| Margaret Kaczor William Blair | Market Perform | Downgrade | Jan 17, 2023 | |
| Robbie Marcus JP Morgan | Neutral | $22 | Maintains | Nov 3, 2022 |
| Mike Matson Needham | Buy | $36 | Maintains | Nov 2, 2022 |
| Mathew Blackman Stifel | Hold | $30 | Maintains | May 9, 2022 |
| Mike Matson Needham | Buy | $45 | Maintains | May 6, 2022 |
Needham | Buy | Upgrade | Dec 9, 2021 | |
| Mathew Blackman Stifel | Hold | $40 | Maintains | Nov 8, 2021 |
When did it IPO
2014
Staff Count
834
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Kevin R. M. Smith
Market Cap
$229.4M
In 2023, INGN generated $315.7M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that INGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Inogen (INGN) shows a hammer chart pattern, suggesting support after recent losses. Upward revisions in earnings estimates may signal a potential trend reversal.
Why It Matters - The hammer chart pattern and rising earnings estimates suggest potential price recovery for Inogen, signaling a possible buying opportunity for investors looking for growth.
Mon, 11 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Inogen reported higher business-to-business sales, contributing positively to its overall results for the third quarter of 2024.
Why It Matters - Inogen's rising B2B sales indicate stronger revenue growth, which can boost investor confidence and potentially lead to increased stock value.
Sat, 09 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Inogen, Inc. (NASDAQ: INGN) will host its Q3 2024 earnings conference call on November 7, 2024, at 5:00 PM ET, featuring key company executives and analysts.
Why It Matters - The announcement of Inogen's Q3 2024 earnings call indicates upcoming insights into the company's financial performance, impacting stock valuation and investor sentiment.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Inogen's Q3 2024 performance is being evaluated against Wall Street estimates and year-ago metrics, highlighting key financial indicators for investors.
Why It Matters - Comparing Inogen's performance metrics against Wall Street estimates and prior year values provides insight into growth trends and market expectations, influencing investor sentiment and stock valuation.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Inogen reported its financial results for Q3 2024, as announced in a press release. Further details on performance metrics were not provided in the excerpt.
Why It Matters - Inogen's Q3 2024 financial results will reveal performance trends, impacting stock valuation and investor confidence regarding growth and profitability in the COPD market.
Thu, 07 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Inogen (INGN) reported a quarterly loss of $0.25 per share, outperforming the Zacks Consensus Estimate of a $0.51 loss, and improving from a loss of $1.97 per share a year prior.
Why It Matters - Inogen's smaller-than-expected loss suggests improving financial health, potentially boosting investor confidence and impacting stock performance positively.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
